Iniciar sesión Regístrese gratis

Inhibrx Ingresos

¿Qué es el Ingresos de Inhibrx?

El Ingresos de Inhibrx, Inc. es $1.634B

¿Cuál es la definición de Ingresos?

El ingreso neto disponible para los accionistas comunes es igual al ingreso neto menos los dividendos preferentes pagados.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Ingresos de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx

¿Qué hace Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Empresas con ingresos similar a Inhibrx